Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84444 | 0.81 | POLB (0.41) | POLBNPSR1L3MBTL1HSD17B10 | |
| SCHEMBL14388360 | 0.77 | KMT2A (0.43) | EPHX2POLBNPSR1L3MBTL1HSD17B10 | |
| SCHEMBL22550134 | 0.77 | LMNA (0.41) | EPHX2POLBNPSR1L3MBTL1 | |
| SCHEMBL16072938 | 0.74 | GAA (0.38) | POLBNPSR1L3MBTL1HSD17B10 | |
| SCHEMBL12227427 | 0.74 | POLB (0.30) | POLBNPSR1L3MBTL1 | |
| SCHEMBL22860158 | 0.74 | EPHX2 (0.41) | EPHX2LIPE | |
| SCHEMBL8263009 | 0.73 | KDM4E (0.46) | EPHX2POLBL3MBTL1 | |
| SCHEMBL8713877 | 0.72 | CA12 (0.48) | EPHX2POLBL3MBTL1 | |
| SCHEMBL2246611 | 0.72 | KDM4E (0.42) | EPHX2 | |
| Hydrochloric Acid SCHEMBL2593006 | 0.71 | KDM4E (0.41) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | EPHX2 1309/4885ADAMTS4 4387/4885MMP13 4431/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | EPHX2 1248/4885ADAMTS4 4378/4885MMP13 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.